Abbott Commits $536M to New Ohio Plant, 450 Jobs for 2026 Startup
Abbott has pledged USD536 million to build a manufacturing plant in Bowling Green, Ohio—creating 450 jobs and targeting full operations in 2026—to localize infant nutrition supply. The company’s leadership in hypoallergenic and medical-grade formulations positions it to capitalize on the market’s shift to premium, high-margin products.
1. Abbott Reports Mixed Fourth-Quarter Results
In its fiscal fourth quarter, Abbott Laboratories delivered revenue of $10.8 billion, up 1.2% year-over-year but coming in below internal guidance of 3% growth. Adjusted earnings per share declined 5% to $0.95 as gross margin contracted by 120 basis points due to elevated input costs and supply-chain inefficiencies. The company’s established cardiovascular and diagnostics divisions showed modest momentum, while its established nutrition portfolio grew just 0.5%, a slowdown from the 4% climb in the prior quarter.
2. Promising Performance in Emerging Segments
Abbott highlighted strength in its diabetes care and neuromodulation businesses, with continuous glucose monitoring systems posting a 12% revenue increase, driven by accelerated adoption in Europe and Asia. The company’s neurostimulation devices also achieved double-digit order growth, supported by new reimbursement approvals in Germany and Japan. Management reiterated plans to invest $500 million in R&D for next-generation implantable technologies over the next two years, aiming to capitalize on aging-population trends and rising chronic-disease prevalence.
3. Landmark Acquisition Enhances Pipeline
In January, Abbott closed its $1.3 billion acquisition of Bigfoot Biomedical, a developer of automated insulin delivery systems. The deal adds a Phase II pump-and-algorithm platform expected to launch in late 2027 and immediate access to Bigfoot’s 15-person diabetes-care development team. Abbott forecasts that the acquired pipeline could contribute up to $600 million in annual revenues by 2030, reinforcing its position in a market projected to exceed $30 billion within five years.
4. Dividend King Status Supports Total-Return Profile
Abbott maintained its 51-year streak of annual dividend increases, approving a 5% hike to $2.28 per share in February. The updated payout represents a 3.3% yield on the company’s 12-month average share count of 1.13 billion. With a payout ratio below 45% of adjusted earnings, management signaled confidence in free cash flows, which reached $5.2 billion in 2025. Investors seeking income can expect dividend growth in the mid-single digits alongside potential upside from emerging-technology catalysts.